EF Hutton Reiterates Buy on Acer Therapeutics, Maintains $7 Price Target

EF Hutton analyst Constantine Davides reiterates Acer Therapeutics (NASDAQ:ACER) with a Buy and maintains $7 price target.

EF Hutton analyst Constantine Davides reiterates Acer Therapeutics (NASDAQ:ACER) with a Buy and maintains $7 price target.

Total
0
Shares
Related Posts